Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the approval and perceived potential of Provenge, a new prostate cancer vaccine, highlighting its capability to extend survival in certain patients while also noting ongoing debates about its cost and mechanisms; it reports no new clinical results.

This review discusses the potential of dental stem cells from deciduous and permanent teeth for tissue regeneration and reports no new experimental results.

This article covers discussions from the Society of Urologic Oncology Annual Meeting outlining that new therapies, such as Provenge, Prostvac, and denosumab, are making the treatment of advanced prostate cancer more complex but may offer extended survival benefits.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This study found that the PVP protocol, combining Peptichemio, vincristine, and 6-methylprednisolone, resulted in remission for diffuse non-Hodgkin's lymphomas with moderate side effects.

HPV infection is linked to better survival in advanced anal cancer, higher radiation doses improve survival, especially in HPV-negative patients, and prostaglandin E₂ pretreatment can protect mouse hair follicles from radiation damage.

This study introduced an innovative antioxidant serum for skin care, using a lipid active from Rana catesbeiana Shaw, and validated its rejuvenating potential through physical-chemical and microbiological tests that ensured its antioxidant effectiveness, microbiological safety, and formulation stability.

This review explores the role of the biomedical esthetician and the potential benefits of platelet-rich plasma in treating hair loss after COVID-19, without presenting new clinical results.

This study suggests that miR-486 may protect against alopecia areata by maintaining hair follicle immune privilege and modulating expression of immune-related genes.

In a laboratory setting, this study found that Biotrinine® dry extract activated hair follicle growth pathways and increased certain growth factor secretions in human dermal papilla cells, suggesting potential benefits for treating chronic hair loss.

This study observed that Ginseng and Albizia extracts, when used together, protected human dermal papilla cells from oxidative stress-induced senescence, and inhibited genes that suppress hair growth, indicating their potential in preventing age-related hair density reduction.

This study suggests that low-dose blue light (453nm) may positively affect hair growth by interacting with the receptors CRY1 and OPN3 in hair follicle cells.

This study suggests that mitochondrial dysfunction might contribute to the pathogenesis of Lichen planopilaris by triggering a metabolic shift that leads to chronic inflammation and hair follicle damage.

This study presented at the ASCO Annual Meeting reported that the epidermal growth factor receptor antibody ABX-EGF showed preliminary efficacy in renal cell cancer patients, with tolerable side effects, while bortezomib demonstrated clinical benefit in a significant proportion of multiple myeloma patients.

This study found that local PGE2 injection may prevent radiotherapy-induced hair loss by protecting hair follicle cells and promoting hair follicle self-repair.

This study found that using valproic acid during radiotherapy for glioma was associated with delayed hair loss and improved survival outcomes.

This article from BJU International discusses the slow progress in prostate cancer research and reports no new findings.

This study found that prostaglandin E2 pretreatment may reduce radiotherapy-induced alopecia by enhancing hair follicle self-repair through transient G1 arrest, suggesting a potential preventive treatment.

In this study, Proxalutamide significantly increased the rate of viral clearance and reduced clinical remission time in patients with mild to moderate COVID-19 compared to placebo.

This study discusses potential connections between geography, stress, and alopecia areata, suggesting that stress is a key factor influencing the condition, alongside geographic factors.

This study reports that both a 9-month-old with phenylketonuria on a phenylalanine-free diet and mice on a deficient diet exhibited severe health issues, highlighting the need for cautious dietary management.

In this report, the author shares experiences from a six-month curricular internship, highlighting activities such as arterial pressure monitoring in a community pharmacy and addressing off-label rituximab use at a hospital, alongside discussions of hair loss treatments and nutritional supplementation for dysphagia in the elderly.

In this study, peptide-based nanoparticles were successfully used to deliver the CRISPR-Cas9 system into cancer cells, effectively targeting and editing KRAS mutations, suggesting promising therapeutic potential for cancer treatment.

This study found that platelet-rich plasma appeared more effective than control treatments as an additional therapy for improving acne scars in several clinical trials.

This article discusses the impact of PROTACs technology in transforming drug discovery with its novel degradation mechanism, but it reports no new experimental findings.

This study found that platelet-rich plasma may be an effective adjuvant treatment for androgenetic alopecia, especially when combined with antiandrogenetic medications and topical minoxidil, though factors like patient age and family history could influence outcomes.

This study found that AR-positive breast cancer cell lines are more sensitive to the dual PI3K/mTOR inhibitor NVP-BEZ235 compared to AR-negative cells.

In this randomized controlled trial, PRP combined with redensyl, saw palmetto, and biotin showed superior efficacy in improving androgenetic alopecia grading scores in male patients when compared to PRP with Procapil.

This study confirmed that an injectable implant known as RISUG-PH™, when administered via the vas deferens, successfully delivers the drug Finasteride to the prostate in male rats for up to 28 days, suggesting a potential localized alternative to oral delivery methods.